ALIM - Spark Newswire

1 minute read

Alimera Sciences Q2 EPS $1.03 Misses $1.06 Estimate, Sales $21.70M Beat $16.04M Estimate

Today, 5:20 PM

Alimera Sciences (NASDAQ:ALIM) reported quarterly earnings of $1.03 per share which missed the analyst consensus estimate of $1.06 by 2.83 percent. This is a 301.96 percent increase over losses of $(0.51) per share from

ALIM

6 minute read

The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO

By Shanthi Rexaline

Today, 5:20 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)

ABVC

2 minute read

Earnings Scheduled For August 13, 2021

By Benzinga Insights

Today, 5:20 PM

Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million.

AIM

2 minute read

How Does Alimera Sciences’s Debt Look?

By Benzinga Insights

Today, 5:20 PM

Over the past three months, shares of Alimera Sciences (NASDAQ:ALIM) fell by 3.92%. Before we understand the importance of debt, let us look at how much debt Alimera Sciences has.

ALIM

1 minute read

News

Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN

By Benzinga Newsdesk

Today, 5:20 PM

Alimera Sciences Europe Limited ("Alimera"), a wholly owned subsidiary of Alimera Sciences, Inc., and Tanner Pharma UK Limited ("Tanner") announced today the initiation of a Named Patient Program for

ALIM

Feed Symbols: ALIM

Alimera Sciences Q2 EPS $1.03 Misses $1.06 Estimate, Sales $21.70M Beat $16.04M Estimate

The Daily Biotech Pulse: Moderna’s Vaccine Produces Durable Response Against Variants, FDA Approves Jazz’s Sleep Disorder Drug, Dermata IPO

Earnings Scheduled For August 13, 2021

How Does Alimera Sciences’s Debt Look?

Alimera Sciences and Tanner Pharma Group Initiate Global Named Patient Program for ILUVIEN